<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02706119</url>
  </required_header>
  <id_info>
    <org_study_id>FPS-INSUPAR-2015-01</org_study_id>
    <nct_id>NCT02706119</nct_id>
  </id_info>
  <brief_title>Insulin in Total Parenteral Nutrition</brief_title>
  <acronym>INSUPAR</acronym>
  <official_title>Subcutaneous Versus Intravenous Basal Insulin in Non-critical Hospitalized Diabetic Patients That Receive Total Parenteral Nutrition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Analyze the level of metabolic control achieved with a routine of regular insulin in the
      parenteral nutrition (PN) reservoir in addition to subcutaneous glargine insulin, versus only
      regular insulin in the PN reservoir.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A pattern of basal insulin (using subcutaneous insulin glargine and regulating the stock as
      prandial), plus regular subcutaneous insulin as rescue, applied to total parenteral nutrition
      (TPN) should be as effective (glycemic control, variability) and safe (hypoglycemia) as the
      usual (regular insulin inside the TPN reservoir and subcutaneous insulin as rescue) in
      patients with type 2 diabetes critics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2016</start_date>
  <completion_date type="Actual">April 4, 2018</completion_date>
  <primary_completion_date type="Actual">March 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Basal blood glucose value before starting TPN</measure>
    <time_frame>Before starting total parenteral nutrition</time_frame>
    <description>Basal glucose value before starting TPN (in mg/dL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Periodical blood glucose</measure>
    <time_frame>Every 6h during 15 days of treatment</time_frame>
    <description>All blood glucose values (in mg/dL) every 6 hours during 15 days of TPN infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Variation of average blood glucose compared with total dose of insulin</measure>
    <time_frame>In days 1, 5 and 15 of treatment</time_frame>
    <description>Variation of average glucose (in mg/dL) compared with total dose of insulin (in mL), in days 1, 5 and 15 of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of hypoglycaemia</measure>
    <time_frame>During TPN treatment up to 15 days</time_frame>
    <description>Number of symptomatic and asymptomatic hypoglycaemia with blood glucose below 70 mg/dL during TPN treatment up to 15 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of severe hypoglycaemia</measure>
    <time_frame>During TPN treatment up to 15 days</time_frame>
    <description>Number of symptomatic and asymptomatic hypoglycaemia with blood glucose below 40 mg/dL during TPN treatment up to 15 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypoglycemia blood glucose values</measure>
    <time_frame>Through study completion, an average of 15 days.</time_frame>
    <description>If the patient refers typical symptoms of hypoglycemia, a measure of blood glucose (in mg/mL) is immediately taken to check the level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypoglycemia symptoms</measure>
    <time_frame>Through study completion, an average of 15 days.</time_frame>
    <description>If blood glucose &lt;70 mg / dL, it is recorded whether or not the patient has symptoms consistent with hypoglycemia and how the episode terminates</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Standard deviation of blood glucose</measure>
    <time_frame>At day 15 of treatment</time_frame>
    <description>Standard deviation of blood glucose (SD): Expressed in milligrams per deciliter (in mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose coefficient of variation (CV)</measure>
    <time_frame>At day 15 of treatment</time_frame>
    <description>Coefficient of variation (CV): Expressed as a percentage (%). The ratio of the standard deviation of the blood glucoses values (in mg/dL) and the average blood glucose (in mg/dL), multiplied by 100.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Infections related with catheter used in parenteral nutrition</measure>
    <time_frame>At day 15 of treatment</time_frame>
    <description>Investigator asses the occurrence of infectious complications in parenteral nutrition catheter. For the evaluation of the infections, temperature is collected daily and patient will perform a blood test weekly. It will be suspected infectious complication for any sudden onset of fever (usually &quot;peaks&quot;), with no other apparent source of infection.</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypertriglyceridemia</measure>
    <time_frame>Every 6h during 15 days of treatment.</time_frame>
    <description>A determination above this value will be considered a complication: Hypertriglyceridemia ≥500 mg/dL</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypernatremia</measure>
    <time_frame>Every 6h during 15 days of treatment.</time_frame>
    <description>A determination above this value will be considered a complication: Hypernatremia &gt;150 mEq/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Hyponatremia</measure>
    <time_frame>Every 6h during 15 days of treatment.</time_frame>
    <description>A determination below this value will be considered a complication: Hyponatremia &lt;135 mEq/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypokalemia</measure>
    <time_frame>Every 6h during 15 days of treatment.</time_frame>
    <description>A determination below this value will be considered a complication: Hypokalemia &lt;3 mEq/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypomagnesemia</measure>
    <time_frame>Every 6h during 15 days of treatment.</time_frame>
    <description>A determination below this value will be considered a complication: Hypomagnesemia &lt;1.2 mg/dL</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypophosphatemia</measure>
    <time_frame>Every 6h during 15 days of treatment.</time_frame>
    <description>A determination below this value will be considered a complication: Hypophosphatemia &lt;2 mg/dL</description>
  </other_outcome>
  <other_outcome>
    <measure>Hyperchloremia</measure>
    <time_frame>Every 6h during 15 days of treatment.</time_frame>
    <description>A determination above this value will be considered a complication: Hyperchloremia &gt;120 mEq/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypocalcemia corrected calcium</measure>
    <time_frame>Every 6h during 15 days of treatment.</time_frame>
    <description>A determination below this value will be considered a complication: Hypocalcemia corrected calcium &lt;8 mg/dL</description>
  </other_outcome>
  <other_outcome>
    <measure>Alteration of liver function markers</measure>
    <time_frame>At day 7 and 15 of treatment</time_frame>
    <description>Alteration of liver function markers is defined as an elevation twice higher than normal limits, according to each laboratory, of two of some of the following parameters (when previously normal): GGT, GOT, GPT, FA or total bilirubin, at least 7 days after initiating TPN.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>At day 15 of treatment</time_frame>
    <description>All adverse events (AEs) are recorded in the case report data since the moment when the patient signs the informed consent. These events will be defined following the organ classification database of MedDRA system.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">163</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Glargine insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose glargine insulin (basal component) + regular insulin within total parenteral nutrition (TPN) reservoir (prandial component). 50% of the total calculated dose of insulin is administered subcutaneously as single dose subcutaneous glargine insulin; remaining 50% of the total calculated dose of insulin is administered as regular insulin in the TPN reservoir. Interventions used: Intravenous glargine insulin, and regular insulin added to TPN bag</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regular insulin added to TPN bag (basal + prandial component). The calculated total dose of insulin is administered as regular insulin in the TPN reservoir. Interventions used: Regular insulin added to TPN bag</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous glargine insulin</intervention_name>
    <description>Glargine insuline is an insulin analogue which has a prolonged duration of action. Insulin glargine is obtained by recombinant DNA technology in Escherichia coli.</description>
    <arm_group_label>Glargine insulin</arm_group_label>
    <other_name>ATC code A10AE0</other_name>
    <other_name>Lantus®</other_name>
    <other_name>Abasaglar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regular insulin added to TPN bag</intervention_name>
    <description>Regular insulin is human insulin produced in Saccharomyces cerevisiae by recombinant DNA technology.</description>
    <arm_group_label>Glargine insulin</arm_group_label>
    <arm_group_label>Regular insulin</arm_group_label>
    <other_name>ATC code A10AB01</other_name>
    <other_name>Actrapid®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (&gt;18 years)

          -  Previously diagnosed with diabetes mellitus.

          -  Hospitalized but without intensive cares.

          -  Have indication of total parenteral nutritional support (TPN, meaning the covering
             over 70% of the estimated daily requirements intravenously) for a minimum of 5 days.

          -  Signature of informed consent.

        Exclusion Criteria:

          -  Diabetes mellitus type 1, diabetes secondary to total pancreatectomy.

          -  Patients with intensive cares.

          -  Patients who have been prescribed TPN in intensive cares unity more than 48 hours
             before admission to hospitalization.

          -  Intradialytic parenteral nutrition.

          -  Patients under 18 or pregnant women.

          -  Patients with renal insufficiency stage 3 B (glomerular filtration rate &lt; 45 mL /
             min).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriel Olveira Fuster, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Regional Universitario de Málaga</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Arquitecto Marcide-Naval</name>
      <address>
        <city>Ferrol</city>
        <state>A Coruña</state>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cabueñes</name>
      <address>
        <city>Gijón</city>
        <state>Asturias</state>
        <zip>33394</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Mérida</name>
      <address>
        <city>Mérida</city>
        <state>Badajoz</state>
        <zip>06800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llátzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Baleares</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Mancha Centro</name>
      <address>
        <city>Alcázar de San Juan</city>
        <state>Ciudad Real</state>
        <zip>13600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Principe de Asturias</name>
      <address>
        <city>Alcalá de Henares</city>
        <state>Madrid</state>
        <zip>28805</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Severo Ochoa</name>
      <address>
        <city>Leganés</city>
        <state>Madrid</state>
        <zip>28911</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30150</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Albacete</name>
      <address>
        <city>Albacete</city>
        <zip>02008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Joan Despi Moisès Broggi (Consorci Sanitari Integral)</name>
      <address>
        <city>Barcelona</city>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de León</name>
      <address>
        <city>León</city>
        <zip>24008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Nuestra Señora de la Candelaria</name>
      <address>
        <city>Tenerife</city>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2016</study_first_submitted>
  <study_first_submitted_qc>March 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2016</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>total parenteral nutrition</keyword>
  <keyword>glargine insulin</keyword>
  <keyword>insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

